J
Justin D. Blasberg
Researcher at Yale University
Publications - 94
Citations - 1433
Justin D. Blasberg is an academic researcher from Yale University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 18, co-authored 79 publications receiving 904 citations. Previous affiliations of Justin D. Blasberg include Harvard University & University of Wisconsin Hospital and Clinics.
Papers
More filters
Journal ArticleDOI
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.
Michelle C. Salazar,Joshua E. Rosen,Zuoheng Wang,Brian N. Arnold,Daniel C. Thomas,Roy S. Herbst,Anthony W. Kim,Frank C. Detterbeck,Justin D. Blasberg,Daniel J. Boffa +9 more
TL;DR: In the National Cancer Database, adjuvant chemotherapy remained efficacious when started 7 to 18 weeks after non–small-cell lung cancer resection, and patients who recover slowly from non-small- cell lung cancer surgery may still benefit from delayed adjuant chemotherapy started up to 4 months after surgery.
Journal ArticleDOI
Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base
Brian N. Arnold,Daniel C. Thomas,Joshua E. Rosen,Michelle C. Salazar,Justin D. Blasberg,Daniel J. Boffa,Frank C. Detterbeck,Anthony W. Kim +7 more
TL;DR: Overall and relative survival in younger patients with NSCLC is better than in older patients, with greater benefit seen in earlier stages, despite having fewer comorbidities and undergoing more aggressive treatment.
Journal ArticleDOI
Motivators, Barriers, and Facilitators to Traveling to the Safest Hospitals in the United States for Complex Cancer Surgery.
Benjamin J. Resio,Alexander S. Chiu,Jessica R. Hoag,Lawrence B. Brown,Marney A. White,Audry Omar,Andres F. Monsalve,Andrew P. Dhanasopon,Justin D. Blasberg,Daniel J. Boffa +9 more
TL;DR: Most of the US public could be motivated to travel to safer hospitals for complex cancer surgery, yet most would require some support to move, although most of the barriers could be overcome with proposed solutions.
Journal ArticleDOI
PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
Jivianne T. Lee,Jamie E. Chaft,Alan Nicholas,Alexander Patterson,S. Waqar,Eric M. Toloza,Eric B. Haura,Dan J. Raz,Karen L. Reckamp,Robert E. Merritt,Dwight H. Owen,David J. Finley,C. Mcnamee,Justin D. Blasberg,Edward B. Garon,John D. Mitchell,Robert C. Doebele,Frank A. Baciewicz,Misako Nagasaka,Harvey I. Pass,Katja Schulze,S. Phan,A. Johnson,Paul A. Bunn,Bruce E. Johnson,Mark G. Kris,David J. Kwiatkowski,I. I. Wistuba,David P. Carbone,V. Rusch +29 more
Journal ArticleDOI
The Society of Thoracic Surgeons Composite Score for Evaluating Esophagectomy for Esophageal Cancer
Andrew C. Chang,Andrzej S. Kosinski,Daniel P. Raymond,Mitchell J. Magee,Malcolm M. DeCamp,Farhood Farjah,Eric L. Grogan,Christopher W. Seder,Mark S. Allen,Justin D. Blasberg,Shanda H. Blackmon,William R. Burfeind,Stephen D. Cassivi,Bernard J. Park,David M. Shahian,David W. Wormuth,Jane M. Han,Cameron D. Wright,Felix G. Fernandez,Benjamin D. Kozower +19 more
TL;DR: The composite rating for esophagectomy has good reliability for programs performing an average of five procedures annually, although almost 60% of participants are not eligible for a star rating because of lower procedure volumes.